Weiguo Qing
Corporate Officer/Principal chez Hutchison MediPharma Ltd.
Profil
Weiguo Qing is currently the Vice President & Head-Oncology Research at Hutchison MediPharma Ltd.
He previously worked as a Principal at Abbott Laboratories and Roche Corp.
He holds a doctorate degree from The University of Texas at Austin and a graduate degree from the Institute of Materia Medica.
Postes actifs de Weiguo Qing
| Sociétés | Poste | Début |
|---|---|---|
Hutchison MediPharma Ltd.
 Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 01/01/2008 |
Anciens postes connus de Weiguo Qing
| Sociétés | Poste | Fin |
|---|---|---|
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
| Roche Corp. | Corporate Officer/Principal | - |
Formation de Weiguo Qing
| The University of Texas at Austin | Doctorate Degree |
| Institute of Materia Medica | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| Entreprise privées | 2 |
|---|---|
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
| Roche Corp. |